Literature DB >> 17572069

Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme.

Mazin A Al-Salihi1, Scott C Ulmer, Thao Doan, Cory D Nelson, Tracy Crotty, Stephen M Prescott, Diana M Stafforini, Matthew K Topham.   

Abstract

Cyclooxygenase-2 is often highly expressed in epithelial malignancies and likely has an active role in tumor development. But how it promotes tumorigenesis is not clearly defined. Recent evidence suggests that this may involve transactivation of the epidermal growth factor receptor through E-prostanoid receptors, but reports differ about the mechanism by which this occurs. We found that E-prostanoid receptors 2-4, but not 1, transactivated the epidermal growth factor receptor. This required metalloproteinase activity, leading to release of growth factors from the cell surface. Both transforming growth factor-alpha and amphiregulin were released in response to over-expression of cyclooxygenase-2, but betacellulin and heparin-binding EGF-like growth factor were not. The metalloproteinase tumor necrosis factor-alpha converting enzyme was required for proteolytic release of transforming growth factor-alpha. We also found that addition of epidermal growth factor receptor ligands to HEK293 cells induced cyclooxygenase-2 expression, suggesting that by activating epidermal growth factor receptor signaling, cyclooxygenase-2 potentially creates a self-perpetuating cycle of cell growth. Consistent with this, inhibition of cyclooxygenase-2 reduced growth of epidermal growth factor receptor over-expressing MCF-10A breast epithelial cells in three-dimensional culture.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17572069      PMCID: PMC2681182          DOI: 10.1016/j.cellsig.2007.05.003

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  35 in total

Review 1.  Prostanoid receptors: subtypes and signaling.

Authors:  R M Breyer; C K Bagdassarian; S A Myers; M D Breyer
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 2.  Shedding of membrane proteins by ADAM family proteases.

Authors:  Marcia L Moss; Millard H Lambert
Journal:  Essays Biochem       Date:  2002       Impact factor: 8.000

3.  Prostaglandin E2 increases growth and motility of colorectal carcinoma cells.

Authors:  H Sheng; J Shao; M K Washington; R N DuBois
Journal:  J Biol Chem       Date:  2001-03-12       Impact factor: 5.157

Review 4.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

Authors:  N Prenzel; O M Fischer; S Streit; S Hart; A Ullrich
Journal:  Endocr Relat Cancer       Date:  2001-03       Impact factor: 5.678

Review 5.  The ADAMs family of metalloproteases: multidomain proteins with multiple functions.

Authors:  Darren F Seals; Sara A Courtneidge
Journal:  Genes Dev       Date:  2003-01-01       Impact factor: 11.361

Review 6.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

7.  Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells.

Authors:  D A Dixon; N D Tolley; P H King; L B Nabors; T M McIntyre; G A Zimmerman; S M Prescott
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

8.  Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice.

Authors:  P C Chulada; M B Thompson; J F Mahler; C M Doyle; B W Gaul; C Lee; H F Tiano; S G Morham; O Smithies; R Langenbach
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

9.  Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice.

Authors:  M Sonoshita; K Takaku; N Sasaki; Y Sugimoto; F Ushikubi; S Narumiya; M Oshima; M M Taketo
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

10.  Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy.

Authors:  Rama Pai; Brian Soreghan; Imre L Szabo; Meredith Pavelka; Dolgor Baatar; Andrzej S Tarnawski
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

View more
  15 in total

1.  Mechanisms Mediating the Synergistic Anticancer Effects of Combined γ-Tocotrienol and Celecoxib Treatment.

Authors:  Amit B Shirode; Paul W Sylvester
Journal:  J Bioanal Biomed       Date:  2011-01-10

2.  Diacylglycerol kinase η modulates oncogenic properties of lung cancer cells.

Authors:  T Nakano; A Iravani; M Kim; Y Hozumi; M Lohse; E Reichert; T M Crotty; D M Stafforini; M K Topham
Journal:  Clin Transl Oncol       Date:  2013-04-10       Impact factor: 3.405

Review 3.  The role of ADAM17 in tumorigenesis and progression of breast cancer.

Authors:  Hongyu Shen; Liangpeng Li; Siying Zhou; Dandan Yu; Sujin Yang; Xiu Chen; Dandan Wang; Shanliang Zhong; Jianhua Zhao; Jinhai Tang
Journal:  Tumour Biol       Date:  2016-09-22

4.  The role of PGE2-associated inflammatory responses in gastric cancer development.

Authors:  Hiroko Oshima; Masanobu Oshima
Journal:  Semin Immunopathol       Date:  2012-10-11       Impact factor: 9.623

5.  Inhibitory effects of omega-3 fatty acids on injury-induced epidermal growth factor receptor transactivation contribute to delayed wound healing.

Authors:  Harmony F Turk; Jennifer M Monk; Yang-Yi Fan; Evelyn S Callaway; Brad Weeks; Robert S Chapkin
Journal:  Am J Physiol Cell Physiol       Date:  2013-02-20       Impact factor: 4.249

6.  The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia.

Authors:  Yasmin Hernandez; John Sotolongo; Keith Breglio; Daisy Conduah; Anli Chen; Ruliang Xu; David Hsu; Ryan Ungaro; Lory A Hayes; Cristhine Pastorini; Maria T Abreu; Masayuki Fukata
Journal:  BMC Gastroenterol       Date:  2010-07-16       Impact factor: 3.067

7.  Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression.

Authors:  Mazin A Al-Salihi; A Terrece Pearman; Thao Doan; Ethan C Reichert; Daniel W Rosenberg; Stephen M Prescott; Diana M Stafforini; Matthew K Topham
Journal:  Cancer Lett       Date:  2008-09-14       Impact factor: 8.679

8.  Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.

Authors:  Don A Delker; Austin C Wood; Angela K Snow; N Jewel Samadder; Wade S Samowitz; Kajsa E Affolter; Kenneth M Boucher; Lisa M Pappas; Inge J Stijleman; Priyanka Kanth; Kathryn R Byrne; Randall W Burt; Philip S Bernard; Deborah W Neklason
Journal:  Cancer Prev Res (Phila)       Date:  2017-11-06

9.  Diacylglycerol kinase δ modulates Akt phosphorylation through pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2).

Authors:  Tracy M Crotty; Tomoyuki Nakano; Diana M Stafforini; Matthew K Topham
Journal:  J Biol Chem       Date:  2012-11-26       Impact factor: 5.157

10.  Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer.

Authors:  G A Doherty; S M Byrne; S C Austin; G M Scully; D M Sadlier; T G Neilan; E W Kay; F E Murray; D J Fitzgerald
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.